Silexion Therapeutics reports positive initial data from SIL204 in orthotopic pancreatic cancer models

Silexion Therapeutics Corp

SIL204 reduced primary tumor bioluminescence by ~70% in AsPC-1 (KRAS G12D) and ~80% in BxPC-3 (wild-type) models by day 28.
In Panc-1 model, SIL204 decreased bioluminescence by 12% vs. baseline while control increased >100% (p<0.05) by day 14.
Subcutaneous SIL204 significantly reduced metastatic spread to liver, intestine, spleen, and stomach in Panc-1 and BxPC-3 models.
Data provide initial validation of systemic delivery efficacy for treating both primary tumors and metastases in orthotopic models.
Company plans to provide updated development strategy leveraging systemic administration approach in coming weeks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.